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niﬁcantly higher health care costs. Efforts to better control
comorbid diseases such as cerebrovascular risk factors may
decrease the future burden of VaD.
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OBJECTIVE: Parkinson’s disease (PD), a progressive neurologi-
cal disorder, affects approximately 1% of the population over 65
in the United States. Average annual Medicaid costs per patient
for all patients were $3759 in 1998. The overall economic
burden of PD was estimated at $25 billion annually in 1997.
This study quantiﬁes direct medical care costs for individual
Medicaid beneﬁciaries with PD. METHODS: Patients with at
least 12 months of continuous enrollment in Medstat’s 
MarketScan® Multi-state Medicaid claims database were iden-
tiﬁed. Patients were required to have either two claims with a
diagnosis of PD (ICD-9-CM 332.0) or one diagnosis and two or
more prescriptions for a PD-related medication (levodopa/
carbidopa, dopamine agonist, MAO-B inhibitor, or COMT
inhibitor). Health care utilization and expenditures accrued from
the ﬁrst observed diagnosis or prescription. Because patients
were allowed to have varying lengths of follow-up (minimum:
12 months), expenditure and utilization data were annualized.
RESULTS: A total of 11,882 patients with PD were identiﬁed
and followed for an average of 821 days. The mean age of the
sample was 73.9 years and 57.6% were women. Mean total
annual health care expenditures were $18,586 (SD $25,592) per
patient. Nineteen percent had at least one hospital admission
while long term care was utilized by 15.8% of patients. Average
annual inpatient hospitalization costs were $8921 (SD $1559),
while long term nursing home care expenditures accounted for
$31,434 (SD $27,659). In addition to PD-speciﬁc care, 16.9%
were diagnosed with a fall or injury and 8.2% with dementia,
while 44.4% were treated with antidepressants and 31.1% were
treated with antipsychotic medications. CONCLUSION: Mean
total health care expenditures for Medicaid patients with PD
were nearly ﬁve times the average Medicaid costs previously
reported for elderly beneﬁciaries. Further investigation of the
burden of PD will entail comparisons to a matched cohort of
Medicaid patients without PD.
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OBJECTIVES: To determine the costs, effects, and cost-
effectiveness of the treatment of Traumatic Brain Injury (TBI)
with calcium channel blockers vs. standard care. METHODS: A
Monte Carlo model of acute TBI was constructed from the
payer’s perspective and used to compare the costs and effects 
of treatment with calcium channel blockers to standard care. 
The intervention modeled was the calcium channel blocker
Nimodipine intravenously, 1mg/hr the for ﬁrst 2 hours and 2
mg/hr thereafter for up to 7 days to control intracranial pressure
(ICP). Standard care is no drug intervention to control ICP. The
outcomes of the model were good recovery, severe disability or
persistent vegetative state (PVS), and death. Outcome probabil-
ities were derived from the literature. Average treatment costs of
TBI were derived from the literature. Modeling and sensitivity
analysis were performed using Data 4.0. The incremental cost,
incremental effectiveness, and incremental cost-effectiveness
were tested using SPSS 11. RESULTS: The incremental cost of
treating TBI with a calcium channel blocker was $15,469 above
standard care (p < 0.001). The incremental effectiveness of treat-
ing TBI was 0.02 Quality Adjusted Life Years (QALY) more than
standard care (p < 0.001). The incremental cost-effectiveness of
treating TBI was $24,030 per QALY (p < 0.001). CONCLU-
SIONS: The incremental cost of treating TBI with a calcium
channel blocker of $15,469 is signiﬁcant, but it is not unrea-
sonable. Considering the severity of the TBI and the importance
that even a small reduction in mortality and disability would
have, the incremental cost of treating TBI with a calcium channel
blocker should not be considered an obstacle to treatment.
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OBJECTIVE: Epilepsy affects up to 1% of the population. With
advances in treatment, up to 90% of epileptics have reasonably
controlled seizures. This has not translated into parity in the
workplace and up to 25% of epileptics remain unemployed. In
this study, we determine those variables that distinguish epilep-
tics who work from those who do not. METHOD: Seventy
patients aged 18–65 years with conﬁrmed epilepsy who did not
undergo epilepsy surgery or vagal nerve stimulator implantation
was randomly selected from our epilepsy database. A 36-item
multiple-choice questionnaire that focused on demographic,
disease-related and employment-related information was sent.
Patients were categorized as being full-time employed, part-time
employed or unemployed. Using a Fischer exact test at a 90%
level of conﬁdence, we identiﬁed those variables that distin-
guished epileptics who were 1) employed (full-time and part-
time) from those who were unemployed, and 2) full-time
employed from non-fulltime employed. RESULTS: Nineteen
questionnaires were returned Patients’ ages ranged from 21 to
59 years and 63% were females. Twenty-six percent were
married and 68% were Caucasians. Thirty-three percent were
employed full-time and 61% were unemployed. Variables that
distinguished epileptics who were employed (either fulltime or
part time) were perceived higher intelligence (p = 0.0429), the
absence of disability beneﬁts (p = 0.0152), shorter history of
seizures (p = 0.0338), and perceived importance of work for both
personal (p = 0.0498) and ﬁnancial (p = 0.0498) reasons. Vari-
ables that distinguished epileptics who were fully employed were
perceived higher intelligence (p = 0.0245), the absence of dis-
ability beneﬁts (p = 0.0498) and perceived importance of work
for personal reasons (p = 0.0537). CONCLUSION: Employment
among epileptics correlates with perceived intelligence, the
absence of disability beneﬁts, the duration of epilepsy and per-
ceived importance of work. Most disease-related variables do not
signiﬁcantly inﬂuence employability. Integrating work-directed
programs into the routine care of epileptics may decrease the
level of unemployment in this population.
